YK1101 TCR‑T cell therapy targeting MAGE‑A4 for advanced solid tumors

Phase I Clinical Study of YK1101 Injection for the Treatment of Advanced Solid Tumors

This will test whether YK1101, a personalized T cell therapy that targets MAGE‑A4, is safe and can help adults with advanced MAGE‑A4–positive solid tumors who are HLA‑A*11:01 positive.

Quick facts

• Phase: PHASE1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Peking University (other)
• Drugs / interventions: cyclophosphamide, prednisone
• Locations: 2 sites (Beijing and 1 other locations)
• Trial ID: NCT07139067 on ClinicalTrials.gov

What this trial studies

This is a single‑arm, open‑label, phase I dose‑escalation study of autologous humanized anti‑MAGE‑A4 T cell receptor‑engineered T cells (YK1101) in patients with advanced solid tumors. Participants must be HLA‑A*11:01 matched and have tumors that are MAGE‑A4 positive by immunohistochemistry (≥2, ≥30%), and they must have measurable disease and prior standard therapy failure or intolerance. The protocol involves collecting peripheral blood mononuclear cells, manufacturing patient‑specific TCR‑T cells, and administering escalating doses to define safety, pharmacokinetics, and preliminary signs of efficacy. Outcomes include safety/tolerability, pharmacokinetic measurements, and early tumor response signals.

Who should consider this trial

Good fit: Ideal candidates are adults (18–75) with histologically confirmed advanced solid tumors that are MAGE‑A4 IHC positive (≥2, ≥30%), HLA‑A*11:01 matched, have at least one measurable lesion, and have failed or cannot tolerate standard therapies.

Not a fit: Patients without MAGE‑A4 expression, those who are not HLA‑A*11:01, or those with early‑stage disease or uncontrolled comorbidities are unlikely to benefit from this treatment.

Why it matters

Potential benefit: If successful, YK1101 could shrink tumors or slow disease in some patients with MAGE‑A4–positive advanced cancers who have exhausted standard treatments.

How similar studies have performed: Other MAGE‑A4–targeted TCR‑T programs have produced tumor responses in early trials, but HLA‑A*11:01–directed, humanized versions like YK1101 are newer and less clinically proven.

Eligibility criteria

Inclusion Criteria:

1. Voluntarily willing to participate in the study and sign the written informed consent form
2. Age ≥18 years and ≤75 years,male or female .
3. Human leukocyte antigen (HLA)-A\*11:01 matched
4. Fresh or formalin-fixed paraffin-embedded (FFPE) samples, immunohistochemistry(IHC)-stained MAGE-A4 positive（+2，≥30%）
5. Histologically-confirmed recurrent/metastatic advanced solid tumors，have failed or relapsed with the standard regimen, or have not tolerated the standard treatment regimen.Including but not limited to synovial sarcoma, myxoid liposarcoma, urothelial carcinoma, esophagogastric junction carcinoma, ovarian carcinoma, esophageal squamous carcinoma, head and neck tumor, non-small cell lung squamous carcinoma, triple negative breast cancer, etc.
6. Patients must have at least one measurable lesion defined by RECIST 1.1.
7. No systemic anti-tumor therapy received within 2 weeks prior to peripheral blood mononuclear cell (PBMC) collection.
8. European Cooperative Oncology Group (ECOG) ≤1 and expected survival time ≥3 months at screening, 24 hours prior to apheresis (APH), lymphodepletion (LD), and infusion
9. Blood oxygen saturation (finger oxygen detection)≥ 95% in a calm and non oxygenated state.
10. Patients must meet the following criteria at screening and before preconditioning (baseline). If any laboratory test result is abnormal referring to the following criteria, it is acceptable to test one more time within 1week. If the test result is still abnormal, the patient is screen failed:

1）Hematology (no intensive blood transfusion (≥2 times within 1week), platelet transfusion or cell growth factor (except for recombinant erythropoietin) performed within 7days before the test): neutrophils (NE) ≥1.5×109 per liter, lymphocytes (LY) ≥0.5×109per liter (except for before preconditioning), platelets (PLT) ≥75×109per liter and hemoglobin (Hb) ≥8.0 g/dL.

2）Blood chemistry: creatinine clearance ≥40 mL/min, alanine aminotransferase (ALT) ≤2.5×ULN, aspartate aminotransferase (AST) ≤2.5×ULN, total bilirubin (TB) ≤1.5×ULN（Gilbert syndrome or liver metastasis subjects ≤ 3 × ULN）, serum lipase and amylase \<1.5 ULN, alkaline phosphatase (ALP) ≤2.5 ULN; for patients with bone or hepatic metastasis, AST, ALT and ALP \<5ULN.

3）Prothrombin time ≤ULN+4 seconds. 11. Women of childbearing potential must have negative serum pregnancy test result at screening and before preconditioning and agree to use an effective and reliable contraceptive method for at least 1 year after the last study treatment. Te acceptable methods include bilateral tubal ligation/bilateral salpingectomy or bilateral tubal occlusion; any approved oral, injection or implantation of hormone; or barrier contraceptive method: condoms containing spermicidal .

Exclusion Criteria:

1. Pregnant or lactating women.
2. HIV, treponema pallidum or HCV serology is positive.
3. Patients with any uncontrolled active infection, including, but not limited to, active tuberculosis or HBV infection (HBsAg positive or HBV DNA positive).
4. Patients with symptomatic central nervous metastases.
5. Patients with AEs induced by previous treatment that have not recovered to Common Terminology Criteria for Adverse Events (CTCAE) ≤1, except for alopecia and other tolerable events judged by the investigator or permitted laboratory abnormalities according to the protocol.
6. Patient allergic or intolerant to preconditioning drugs, including, but not limited to, fudarabine and cyclophosphamide ; allergic to the components of YK1101; penicillin allergy history confrmed by positive skin test; or any severe allergy history-for example, anaphylactic shock.
7. Patients who have undergone coronary artery reconstruction in the past.
8. The patient's tumor lesion invades large blood vessels and has a significant risk of bleeding.
9. Thrombosis and embolism occurred 6 months before cell transfusion.
10. Patients who have undergone major surgery or severe trauma within 4weeks before apheresis .
11. Patients who have a history of organ transplantation or are waiting for organ transplantation.
12. Patients with other serious diseases that may restrict them from participating in this study, such as poorly controlled diabetes (glycosylated hemoglobin HbA1c \>8% undertreatment), poorly controlled hypertension judged by the investigator (blood pressure \>160mmHg/100mmHg), severe cardiac insufficiency (left ventricular ejection fraction \<50%), myocardial infarction or unstable arrhythmia or unstable angina pectoris, pulmonary embolism, chronic obstructive pulmonary disease, interstitial lung disease or clinically significant lung function test abnormalities in the past 6months.
13. Patients who are expected to continue using immunosuppressive therapy during the trial (excluding physiological replacement therapy with glucocorticoids, such as prednisone\<10mg/d or equivalent doses)
14. Patients who require long-term use of aspirin or anticoagulant drugs.
15. Patients who have participated in other intervention clinical trials within 2 weeks.
16. Patients with adverse drug addiction or a history of drug abuse.
17. Patients who are unable or unwilling to comply with the clinical protocol, by the investigator's judgment.

Where this trial is running

Beijing and 1 other locations

• Department of GI Oncology, Peking University Cancer Hospital Recruiting Beijing, Beijing, China, 100142 — Beijing, China (NOT_YET_RECRUITING)
• Peking University Cancer Hospital & Institute — Beijing, China (RECRUITING)

Study contacts

• Study coordinator: Lin Shen

Conditions: Advanced Solid Tumor Cancer, Biological: TCR-T therapy, Phase I